STC-15 was well tolerated and clinical activity was observed across the pharmacologically active dose range in advanced cancer patients Primary objectives were achieved to progress STC-15 into combination with checkpoint inhibitor combination studies STORM...
WATERTOWN and CAMBRIDGE, Mass., May 23, 2024- In a significant development for the RNA biotechnology sector, Orna Therapeutics has announced the acquisition of ReNAgade Therapeutics. The financial terms of the acquisition were not disclosed. Background on ReNAgade...
PARIS and BOSTON, April 22, 2024 – In a significant development in the biopharmaceutical industry, Ipsen and Skyhawk Therapeutics have entered into an exclusive global agreement to advance the discovery and development of novel small molecules that target RNA. These...
The review sheds light on the role of post-transcriptional RNA modifications in normal hematopoietic development and acute myeloid leukemia, and highlights novel therapeutic targets and treatment approaches. Credit: Chinese Medical Journal The hematopoietic system is...
CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage immunology company, today announced it will be providing updates on its RNA immunotherapies at multiple presentations at the American Association...
